UNISOUND AI TECHNOLOGY CO., LTD.
雲知聲智能科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 9678)

VOLUNTARY ANNOUNCEMENT
OFFICIAL LAUNCH OF SELF-DEVELOPED MEDICAL IMAGING MULTI-MODAL LARGE MODEL "U2-RADIMED"

This announcement is made by Unisound AI Technology Co., Ltd. (the "**Company**") on a voluntary basis to inform the shareholders and potential investors of the Company of its latest technological developments.

Following the launch of the U2-Med Tri-Medical LLM, the Company recently officially launched its self-developed medical imaging multi-modal large model, "U2-RadiMed". The model is the first full-chain imaging large model in China that deeply integrates medical image understanding, report generation, clinical reasoning and decision-making, and visual question answering. It supports multi-modal mixed inputs of single or multiple images and text, comprehensively covers mainstream medical imaging types such as CXR (chest X-ray), CT, and MRI, and has established a framework of six core capabilities: report generation, lesion detection and localization, clinical reasoning, clinical decision-making, general medical VQA, and advanced medical reasoning. It can complete the entire work loop of "viewing images → retrieving knowledge → performing reasoning → drawing conclusions". In multiple authoritative horizontal evaluations, U2-RadiMed ranked first in the general comprehensive evaluation with an overall score of 55.47, surpassing domestic and international models such as Gemini 3.1 and GPT-5.4; in the specialized evaluations of the six core capabilities, it secured first place in four categories: report generation, lesion detection and localization, general medical VQA, and advanced medical reasoning. Among these, it significantly outperformed similar models in lesion detection and localization with a score of 37.58; and ranked first among the evaluated models in the MedBench 5.0 full-modality large model evaluation with an overall score of 57.2.

At the application level, U2-RadiMed overcomes the limitations of traditional AI in single-image analysis. It can understand the relational logic between multi-temporal images, supporting diverse clinical scenarios such as lesion detection and localization, multi-temporal image comparison, dynamic tracking of disease progression, differential diagnosis, and assisted report generation. It provides clinicians with comprehensive AI-assisted support, from lesion screening and precise diagnosis to individualized treatment decision-making. Currently, the model has been launched on the Company's MaaS platform (Token Hub). It supports multi-image input and a 40K context, enabling out-of-the-box use of the model's capabilities, and can be quickly integrated with the radiology departments and clinical diagnosis and treatment scenarios of medical institutions at all levels.

The launch of U2-RadiMed marks the official entry of the Company's large model capabilities into the more complex and professional core clinical scenario of medical imaging, further perfecting the Company's medical AI product system of "general foundation large model — tri-medical professional large model — medical imaging multi-modal large model", and consolidating the Company's technological leadership in the field of medical artificial intelligence. In the future, the Company will continue to deepen the application and innovation of large models in the pan-medical field, drive the transition of medical imaging AI from technological breakthroughs to real medical productivity, help medical institutions improve quality and efficiency, and create long-term value for the Company's shareholders.

By Order of the Board
Unisound AI Technology Co., Ltd.
Dr. Huang Wei
Executive Director and Chief Executive Officer

Beijing, the PRC
August 13, 2026

As at the date of this announcement, the Board of Directors of the Company comprises: (i) Dr. Liang Jia'en, Dr. Huang Wei, Dr. Kang Heng, Dr. Li Xiaohan and Dr. Liu Shengping as executive directors; and (ii) Mr. Hu Jianjun, Dr. Fan Jian, Dr. Jin Huihua and Dr. Zhang Kun as independent non-executive directors.